Low-dose compared with stand ard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associ ated with human immunodeficiency virus infection
Kaplan LD, Straus DJ, Testa MA, et al. Low-dose compared with stand ard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associ ated with human immunodeficiency virus infection. N Engl J Med 1997; 336:1641-8.
Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: Results of a tree-structured survival analysis
Kwak LW, Halpern I, Olshen RA, Horning SJ. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol 1990;8:963-77.
The role of dose intensity in determining outcome in intermediate-grade non-Hodgkin's lymphoma
Meyer RM, Hryniuk WM, Goodyear MD. The role of dose intensity in determining outcome in intermediate-grade non-Hodgkin's lymphoma. J Clin Oncol 1991;9:339-47.
Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma
Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328:1002-6.
Pilot trial of infiisional cyclophosphamide, doxorubicin, and etoposide plus didanosine and filgrastim in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma
Sparano JA, Wiernik PH, Hu X, et al. Pilot trial of infiisional cyclophosphamide, doxorubicin, and etoposide plus didanosine and filgrastim in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma. J Clin Oncol 1996;14:3026-35.
Human immunodeficiency virus-related lymphoma treatment with intensive combination chemotherapy
Gisselbrecht C, Oksenhendler E, Tirelli U, et al. Human immunodeficiency virus-related lymphoma treatment with intensive combination chemotherapy. Am J Med 1993;95:188-96.